
Results presented at the American College of Rheumatology/Association of Rheumatology Professionals 2012 annual meeting show that adalimumab and methotrexate are more effective than DMARDs and prednisone in achieving remission in patients with early rheumatoid arthritis or undifferentiated arthritis patients.